Results 251 to 260 of about 3,347,409 (388)

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran   +10 more
wiley   +1 more source

Adrenal aldosterone synthase (CYP11B2) histopathology and its association with disease-induced sudden death: a cross-sectional study. [PDF]

open access: yesLancet Reg Health Eur
Ylänen A   +11 more
europepmc   +1 more source

Longest survivor of pulmonary atresia with ventricular septal defect without surgical intervention

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1499-1507, April 2025.
Sang Zhou   +5 more
wiley   +1 more source

Lower left ventricular ejection time in MYBPC3 variant carriers with overt or subclinical hypertrophic cardiomyopathy

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Hypertrophic cardiomyopathy (HCM) is an inherited cardiomyopathy often caused by pathogenic variants in MYBPC3 and MYH7, encoding myosin‐binding protein C3 and myosin heavy chain 7, respectively. These variants can cause increased actin–myosin crossbridge cycling, resulting in ventricular hypercontractility, but mice lacking Mybpc3 ...
Isabell Yan   +10 more
wiley   +1 more source

Sudden Cardiac Death Risk Stratification and Prevention in Chagas Disease: A Non-systematic Review of the Literature

open access: yesArrhythmia & Electrophysiology Review, 2020
Roberto Keegan   +2 more
doaj   +1 more source

Transcriptomic Profiling of Human Myocardium at Sudden Death to Define Vulnerable Substrate for Lethal Arrhythmias. [PDF]

open access: yesJACC Clin Electrophysiol
Caudal A   +13 more
europepmc   +1 more source

Angiotensin receptor‐neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Angiotensin receptor‐neprilysin inhibitor (ARNI) therapy has demonstrated improved outcomes in heart failure with reduced ejection fraction (HFrEF). However, its benefits in patients with concomitant kidney failure undergoing replacement therapy remain uncertain. Methods and results Using the National Health Insurance Service database, we
Mi‐Hyang Jung   +8 more
wiley   +1 more source

Sudden Unexplained Nocturnal Death Syndrome: The Hundred Years' Enigma

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Jingjing Zheng   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy